Manufacturing

Articles

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.

Abzena Invests in New $60-Million CGMP Manufacturing Facility

Melisa Carpio is a global technology consultant for Cell Culture Technologies at Sartorius North America.

Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.

Current Challenges with Cell Culture Scale-up for Biologics Production 

Glycoengineering is growing in importance as a technique to improve antibody therapeutic efficacy, safety, and product quality. 

Glycoengineering Shows Promise for Enhancing Antibody Therapeutics

The technology is a novel, plasmid-free manufacturing system for robust and reproducible manufacture of AAV at scale.

Oxgene Launches TESSA Technology for AAV Manufacture at Scale

The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.

Lonza, Humanigen Partner to Expand Manufacturing of Lenzilumab for Potential COVID-19 Therapy

The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.

Novavax in COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India

The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.

Lilly and Amgen in Manufacturing Collaboration for COVID-19 Antibody Therapies

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.

Manufacturing, Biologics